ATC Group: G04CA02 Tamsulosin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04CA02 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04C Drugs used in benign prostatic hypertrophy
4 G04CA Alpha-adrenoreceptor antagonists
5 G04CA02 Tamsulosin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.4 mg

Active ingredients in G04CA02

Active Ingredient Description
Tamsulosin

Tamsulosin binds selectively and competitively to post-synaptic α1-adrenoreceptors, prevailingly their subtypes designated α1A and α1D. Thus relaxation of smooth muscles of the prostate and urethra is achieved, which leads to a reduction of tonus and an improvement of the urinary flow.

Related product monographs

Title Information Source Document Type  
CONTIFLO XL Prolonged release capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FLOMAX Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
FLOMAXTRA Film-coated prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OMNIC Modified release capsule, hard Web Search MPI, EU: SmPC
OMSULA Prolonged-release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TAMSULOSIN ZENTIVA Prolonged-release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TANYZ Hard modified-release capsule Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Cyprus (CY)

Estonia (EE)

France (FR)

Hong Kong (HK)

Israel (IL)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

Singapore (SG)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.